Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that occurs naturally throughout the human body, produced in the gut, pancreas, and central nervous system. Unlike most of the compounds on this site, which are synthetic analogs designed for a narrow purpose, VIP is a broadly distributed signaling molecule with a wide research footprint.
Where VIP Shows Up in the Body
VIP receptors are distributed across the gut, lungs, immune cells, and brain, which is part of why the research literature on it spans such different territory — from gastrointestinal motility to circadian-clock regulation in the suprachiasmatic nucleus to immune-modulatory roles in inflammatory conditions.
The Chronic Inflammatory Response Syndrome (CIRS) Context
VIP has drawn attention in the research-use community specifically around chronic inflammatory response syndrome protocols, an area associated with the work of Dr. Ritchie Shoemaker. This remains a niche and actively debated area of clinical research rather than an established, consensus application, and anyone researching it should treat the underlying CIRS framework itself as an area of ongoing scientific discussion.
Why VIP Isn’t a “Beginner” Research Peptide
Because VIP acts on vascular tone (hence “vasoactive”) and multiple organ systems simultaneously, its research use profile is broader and less predictable than a targeted peptide like BPC-157. This makes it a compound best approached with a specific research question in mind rather than general interest.
Sourcing
VIP is available for research purposes through the following vendor.